Skip to main content
logo
Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
5.05
-0.15 (-2.88%)
At close: Sep 1, 2026, 4:00 PM EDT
5.10
+0.05 (0.99%)
Pre-market: Sep 2, 2026, 7:05 AM EDT

Unicycive Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---0.680.95-
Revenue Growth
----29.02%--
Gross Profit
---0.680.95-
Selling, General & Admin
23.5520.412.18.556.572.9
Research & Development
9.589.1220.0112.912.446.08
Operating Expenses
33.1329.5232.1221.45198.98
Operating Income
-33.13-29.52-32.12-20.77-18.05-8.98
Interest Expense
-0.06-0.07-0.07-0.08-0.01-0.63
Interest & Investment Income
1.471.011.260.62--
Other Non Operating Income (Expenses)
-3.52.02-5.8-10.3--
EBT Excluding Unusual Items
-35.22-26.56-36.73-30.54-18.06-9.61
Other Unusual Items
------0.41
Pretax Income
-35.22-26.56-36.73-30.54-18.06-10.02
Net Income
-35.22-26.56-36.73-30.54-18.06-10.02
Preferred Dividends & Other Adjustments
--1.10.87--
Net Income to Common
-35.22-26.56-37.82-31.41-18.06-10.02
Net Income Growth
------
Shares Outstanding (Basic)
23167221
Shares Outstanding (Diluted)
23167221
Shares Change
107.81%137.17%172.97%62.98%28.96%37.37%
EPS (Basic)
-1.56-1.67-5.65-12.80-11.99-8.58
EPS (Diluted)
-1.56-1.67-5.65-12.80-11.99-8.58
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-27.85-31.34-28.65-18.3-15.65-5.8
Free Cash Flow Per Share
-1.23-1.97-4.28-7.46-10.40-4.96
Gross Margin
---100.00%100.00%-
Operating Margin
----3077.63%-1898.21%-
Profit Margin
----4653.48%-1898.84%-
Free Cash Flow Margin
----2710.37%-1645.95%-
EBITDA
-33.09-29.48-32.1-20.77-18.05-8.98
D&A For EBITDA
0.030.030.020.010.010
EBIT
-33.13-29.52-32.12-20.77-18.05-8.98
SEC Filings: 10-K · 10-Q